Clinical Trial Update: Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update on an allogeneic CD19/BCMA-targeted CAR-γδT cell therapy assessing safety and preliminary pharmacodynamics in refractory autoimmun…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis
• Connective Tissue Disease-associated Thrombocytopenia
• Idiopathic Inflammatory Myopathy
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• Allogeneic CD19/BCMA-targeted CAR-γδT Cell Therapy

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Refractory/Relapsed Systemic Lupus Erythematosus, Refractory / Relapsed / Progressive Systemic Sclerosis | Phase 1 | Status: NOT_YET_RECRUITING